Previous 10 | Next 10 |
home / stock / alpmf / alpmf news
2023-04-24 08:39:37 ET For further details see: Lantheus, POINT Biopharma receive FDA Fast Track status for prostate cancer candidate
2023-04-19 06:39:26 ET Summary Biotechnology is the second worst performer in healthcare, significantly lagging behind the US market year-to-date. However, there could now be opportunities to get a bargain in the biotechs. Kura Oncology may be of interest to investors as this US b...
2023-04-04 08:35:08 ET Summary Its lead drug candidate is in Phase 3 development for multiple leukemia indications. Mechanism has utility in other cancer and non-cancer diseases. Perceived trial delays punished the stock. Delays actually raise the odds of greater survival ...
2023-04-01 16:00:21 ET Pfizer's ( NYSE: PFE ) acquisition of Seagen ( NASDAQ: SGEN ), announced in March, is expected to complement the pharma giant's current portfolio of oncology therapies. Seagen focuses on antibody-drug conjugates (ADCs), a technology that the co...
2023-03-29 04:41:23 ET Astellas Pharma ( OTCPK:ALPMF ) ( OTCPK:ALPMY ) is collaborating with Roche Diabetes Care Japan to develop and commercialize Roche's Accu-Chek Guide Me blood glucose monitoring system as a combined product with an app called BlueStar. Astellas s...
2023-03-15 09:10:29 ET The Biden administration on Wednesday published a list of 27 Medicare Part B drugs that will be subject to inflation penalties for the first time in the U.S., including some key pipeline products from AbbVie ( ABBV ), Gilead ( GILD ), and Seagen ( SGEN ...
2023-03-13 08:07:25 ET Bristol Myers ( NYSE: BMY ), Pfizer ( NYSE: PFE ), and AbbVie ( NYSE: ABBV ) are among firms likely to face Medicare price negotiations for some of the key blockbuster medications, Reuters reported Monday, citing five Wall Street and ac...
2023-03-05 12:00:42 ET Cancer drugmaker Seagen ( NASDAQ: SGEN ) had reportedly drawn interest from two pharma giants in less than a year, indicating a bidding war not seen since Horizon Therapeutics ( HZNP ) sparked a buyout fight which Amgen ( AMGN ) won in late 2022. ...
Merck ( NYSE: MRK ) is discontinuing a phase 3 trial of a Keytruda combination treatment for prostate cancer after the study failed its main goals, while another late stage trial of the blockbuster drug did not meet its main objectives to treat a type of lung cancer. Prostate c...
Summary Astellas came in with a mixed set of results, with growth across product segments balanced by challenges in U.S. sales. We are unsure about generic competitors posing a threat to XTANDI's market share. Profitability and economic profit continue to remain a standout, despite ...
News, Short Squeeze, Breakout and More Instantly...
Astellas Pharma Inc Company Name:
ALPMF Stock Symbol:
OTCMKTS Market:
Pharmaceutical stocks were initially expected to be largely immune to the COVID-19 economic downturn. Drugmakers, after all, generally produce products that are essential to daily life. However, the extreme social distancing that has become part and parcel of this unusual period has halted nume...
One of England's top healthcare watchdogs, the National Institute for Health and Care Excellence (NICE), has officially decided to stay the course and reject AstraZeneca 's (NYSE: AZN) lung cancer drug Tagrisso. A few months ago, the pharmaceutical giant argued that the drug should receive...
This past year proved profitable for investors in Incyte (NASDAQ: INCY) and Seattle Genetics (NASDAQ: SGEN) . Handily beating broad market and biotech indexes, these two drug manufacturers hit the $20 billion valuation mark and are poised to continue growing in the coming year -- unless, ...